Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the United States Patent and Trademark Office has issued to Idera patent number 8,486,908, providing both composition of matter and method of use protection for IMO-8400. IMO-8400, an antagonist of Toll-like receptors (TLRs) 7, 8, and 9, is Idera’s lead candidate in development for the treatment of autoimmune diseases. IMO-8400 is currently being evaluated in a Phase 2 trial in patients with moderate-to-severe plaque psoriasis.
Help employers find you! Check out all the jobs and post your resume.
